semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.5-999.0,  Quality of Life Endometrial Cancer Surgery--Complications Gynecologic Cancer Woman over 18 years of age scheduled for primary surgery for histologically verified endometrial cancer (regardless of histological type or degree) tumor clinically restricted to the uterus (presumptive FIGO stage I or II) speaks and reads Swedish capable of completing the questionnaire independently  Clinical or radiological cancer outside the uterus preoperative radio / chemotherapy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rotator Cuff Tear Arthropathy Shoulder Osteoarthritis Aged 18 years or older 2. Diagnosed with rotator cuff arthropathy, glenohumeral osteoarthritis with a > 1.5-cm rotator cuff tear, or massive irreparable rotator cuff tear 3. Have a normal functioning deltoid 4. Have preserved teres minor function (a negative Hornblower's sign) 5. Have failed conservative management for >3 months  younger than 18 years 2. chronic opiate use history 3. fibromyalgia or other conditions that increase susceptibility to pain 4. preoperative stiffness (definition: < 30 degree passive external rotation, < 90 degree passive forward elevation), neurologic disorder affecting the ipsilateral upper extremity, 5. RTSA for acute proximal humerus fracture or fracture sequelae (nonunion, malunion) 6. previous arthroplasty, fracture fixation, or open rotator cuff procedures in the same shoulder 7. deltoid dysfunction 8. inflammatory glenohumeral arthritis 9. non-English speaking or unable to understand English for consent
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 11.0-999.0,  Sickle Cell Disease diagnosis of SCD as reported by provider self-reported history of pain at least once per month caregiver/parent willingness to participate owns a smartphone  not under the care of a provider participant cognitive disability or delay that precludes ability to participate, defined as classified severe neurocognitive deficits as documented by neuropsychological evaluation in the medical record lack of wi-fi access
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Primary Hormone Receptor Positive Breast Cancer Patients with histologically-confirmed, HR-positive (ER and/or PR) stage 1-3 breast cancer Completed anti-HER2 therapy, if HER2-positive Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression At least 3 months post completion of chemotherapy, if administered At least 3 months post radiation, if administered Receiving adjuvant endocrine therapy with an aromatase inhibitor (anastrozole, letrozole, exemestane) ECOG performance status of 0 to 1 Sedentary (i.e., <150 minutes / week of exercise) Age ≥ 18 BMI ≥ 27  Presence of metastatic disease Insulin-dependent diabetes mellitus or non-insulin dependent diabetes mellitus on medical therapy Enrollment onto any other therapeutic investigational study Mental impairment leading to inability to cooperate Any of the following contraindications to exercise: 1. Acute myocardial infarction within 3-5 days of any planned study procedures; 2. Unstable angina 3. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise 4. Recurrent syncope 5. Active endocarditis 6. Acute myocarditis or pericarditis 7. Symptomatic severe aortic stenosis 8. Uncontrolled heart failure 9. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures 10. Thrombosis of lower extremities 11. Suspected dissecting aneurysm 12. Uncontrolled asthma 13. Pulmonary edema 14. Respiratory failure 15. Acute non-cardiopulmonary disorders that may affect exercise performance Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation Nut or legume allergy Concurrent participation in weight loss or other exercise programs
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-45.0,  Human Papilloma Virus Female between the ages of 16 and 45 years of age at enrollment Postpartum (Day 1 vaccination to occur within 1 week of delivery) Judged to be in good health on the basis of medical history and physical examination Able to fully understand study procedures, alternative treatments available, the risks involved in the study and voluntarily agrees to participate by giving written informed consent Able to read, understand, and complete the questionnaires  Has a known allergy to any vaccine component, including aluminum, yeast, or Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition Is receiving or has received in the year prior to enrollment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monoclonal antibody therapies (including rituximab), intravenous gamma globulin (IVIG), antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (within 2 weeks of enrollment) received such therapy, or has received 2 or more courses of high dose corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to enrollment. The use of inhaled, nasal, or topical steroids are considered eligible for the study Has received any immune globulin product (including RhoGAM™) or other blood derived product within 3 months prior to Day 1 vaccination or plans to receive such product during the study Has received a marketed HPV vaccine Has had a fever of > 100° within 24-hour period prior to the Day 1 vaccination
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coronavirus Infections Adults healthcare workers (HCW) OR Chronic patients with at least 2 chronic medical conditions  People that have been in contact with people positive for COVID-19 in the previous 14 days People with body temperature >37.5°C People with Dry cough People with Respiratory distress (Respiratory Rate >25/min or O2 Saturation <92%)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 17.0-999.0,  Influenza Vaccination Health Promotion Health Behavior Risk Reduction Current Geisinger patient at the time of study Falls in the top 10% of patients at highest risk, as identified by the flu-complication risk scores of Medial's machine learning algorithm (which operates on coded EHR data) May limit to patients that are under Geisinger primary care, depending on algorithm performance of patients who have non-Geisinger PCPs  Has contraindications for flu vaccination Has opted out of receiving communications from Geisinger via all of the modalities being tested
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coronavirus Disease 2019 (COVID-19) Respiratory Illness Corona Virus Infection COVID-19 Over 18 years of age Healthcare worker This is defined as anyone who works in a healthcare setting or has face to face contact with patients Provide a signed and dated informed consent form Australian sites only: If annual influenza vaccination is available, receiving the flu vaccine is an requirement. The flu vaccine will be required a minimum of 3 days in advance of randomisation in the BRACE trial Pre-randomisation blood collected  Has any BCG vaccine contraindication Fever or generalised skin infection (where feasible, randomisation can be delayed until cleared) Weakened resistance toward infections due to a disease in/of the immune system Receiving medical treatment that affects the immune response or other immunosuppressive therapy in the last year These therapies systemic corticosteroids (≥20 mg for ≥2 weeks), non-biological immunosuppressant (also known as 'DMARDS'), biological agents (such as monoclonal antibodies against tumour necrosis factor (TNF)-alpha) People with congenital cellular immunodeficiencies, including specific deficiencies of the interferon-gamma pathway People with malignancies involving bone marrow or lymphoid systems People with any serious underlying illness (such as malignancy) NB: People with cardiovascular disease, hypertension, diabetes, and/or chronic respiratory disease are eligible if not immunocompromised, and if they meet other Known or suspected HIV infection,even if they are asymptomatic or have normal immune function
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pelvic Organ Prolapse Stage II-IV pelvic organ prolapse Bothersome bulge symptoms At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form English-speaking Undergoing treatment of prolapse Surgery occurring at least 7 days from date of randomization (to allow for collection of at least 7 days of preoperative accelerometer data) Able and willing to follow up at 3 months for in-office exam  Enrollment in another research study of pelvic organ prolapse Concomitant non-urogynecologic surgery Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  COVID-19 to. Covid 19 positives b. Some of the characteristic symptoms of covid 19: fever, odynophagia, respiratory distress. c. Age between 18 years and 80 years to. Covid 19 negatives b. Kidney failure IV / VI. c. Congestive heart failure. d. Patients taking anticoagulants, particularly warfarin sodium
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Neoplasm Malignant Female women between 18 and 70 years old patient with histologically confirmed breast cancer adjuvant situation spoken language : french patient who never had chemotherapy in the past  Patient unable to sit Malformation of the back Wound at the level of the zones to massage Patient placed under the authority of a tutor Pregnant patient
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-48.0,  Osteoporosis Cardiovascular Risk Factor Participants were healthy premenopausal women volunteers between the ages of 30 and 48 years Participants were free of chronic back or joint problems, cardiovascular disease, non-smokers, not pregnant, not taking antihypertensive drugs or any medication that affects bone density Participants didn't have regularly participated in a weight training program and yoga exercise at least 12 months prior to the study Participants were medically stable, ambulatory, and capable of training  Individual who were outside of the 30-48 years age range and who exceed the weight limit of the DXA (300 pounds) Individuals who did not have the regular menstrual cycles Pregnancy or the possibility of becoming pregnant during the intervention period Individuals who were taking medications known to affect bone metabolism such as steroid hormones, calcitonin, or corticosteroids Any persons with physical and mental disabilities preventing them from being trained, including orthopedic or arthritic problems, were not allowed to participate Individuals whose radiation exposure from medical and/or research tests in the previous year exceeds the recommended regulator limit
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Influenza, Human Male or female, between 18 and 55 years old (extremes included) at screening. 2. In good physical and mental health as determined on the basis of medical history and general physical examination performed at screening. 3. Absent or low levels of detectable pre-existing antibodies to influenza virus subtypes, including as a minimum the challenge strain, as determined by a MNT titre of ≤ 20 at screening. 4. Negative urine test for selected drugs of abuse at screening and upon check-in at the clinical site. 5. Negative alcohol breath test 6. Female subjects should fulfil one of the following 1. At least 1 year post-menopausal (amenorrhea >12 months and/or follicle-stimulating hormone (FSH) > 30 mIU/mL) prior to screening; 2. Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation); 3. Will use contraceptives as outlined in criterion 8 from screening to discharge. 7. Female subjects of childbearing potential and male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control from screening to discharge  Subjects who have received any vaccination within the last 3 months prior to screening or influenza vaccine within the last 12 months prior to screening or who anticipate receiving this during the study. 2. Subjects with a diagnosis of influenza or influenza-like illness confirmed by a physician within the last 6 months prior to screening. 3. Subjects with a positive result for adventitious agent screening (qualitative PCR testing) for any respiratory virus or bacteria on Day -2. 4. Haematology and chemistry parameters, pulse rate and/or blood pressure, and ECG outside the reference range for the population studied and considered as clinical significant by the Investigator. 5. Has an acute or chronic medical condition
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  COVID Sars-CoV2 Age ≥18 years Laboratory-confirmed SARS-CoV-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of COVID-19 disease Patients must have adequate organ and marrow function measured within the last 6 months Subjects must have at least one of the following high-risk features for clinical deterioration Hypertension Diabetes Mellitus Moderate to severe Chronic Obstructive Pulmonary Disease, Emphysema, Cystic Fibrosis, or Asthma Cancer patients who have received any immunosuppressive drugs within a year from enrollment Sickle Cell disease or thalessemia Age > or = 50  Severe or life threating COVID Weight less than 45 kg Pregnant or breast-feeding females Subjects on dialysis or with creatinine clearance < 45 ml/min Existing DMID Toxicity Scale for Determining Severity of Adverse Events grade 3 or greater hepatic failure Previously documented moderate or severe retinopathy or macular degeneration Uncontrolled Seizure disorder Prolonged QT, defined as QTc ≥470 milliseconds for men and as QTc ≥480 for women using Bazett's formula Known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial Currently receiving any study medications for other indications